Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 5:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 167 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: etanercept (Enbrel) Clear all
Completed Phase 4 Interventional Results available

Anti-inflammatory Therapy to Improve Outcomes After TPIAT

NCT02713997
View directory record Official record
Conditions
Pancreatitis, Chronic; Diabetes; Transplant
Interventions
etanercept, Alpha 1-Antitrypsin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 24, 2026, 5:16 PM EDT
Completed Phase 4 Interventional Results available

A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

NCT01331837
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
3,080 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
143
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 125 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Sep 24, 2026, 5:16 PM EDT
Completed Phase 3 Interventional Results available

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

NCT02471144
View directory record Official record
Conditions
Chronic Severe Plaque-type Psoriasis
Interventions
Experimental : Secukinumab low dose, Experimental: Secukinumab high dose, Placebo Comparator: Secukinumab Placebo, Active Comparator: Etanercept
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 24, 2026, 5:16 PM EDT
Completed No phase listed Observational Results available

Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project

NCT00116272
View directory record Official record
Conditions
Pregnancy
Interventions
Etanercept
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Female only
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 24, 2026, 5:16 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women With Rheumatoid Arthritis and the Effect of Treatment With Etanercept

NCT00034060
View directory record Official record
Conditions
Rheumatoid Arthritis, Healthy
Interventions
Etanercept
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 24, 2026, 5:16 PM EDT
Completed Phase 1 Interventional

Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors

NCT00201812
View directory record Official record
Conditions
Tumors
Interventions
Etanercept, Docetaxel, Dexamethasone
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Sep 24, 2026, 5:16 PM EDT
Completed No phase listed Observational Results available

Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab

NCT01981473
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
no intervention
Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
34
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Sep 24, 2026, 5:16 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

ASIS for Enbrel in Plaque Psoriasis

NCT02112097
View directory record Official record
Conditions
Plaque Psoriasis.
Interventions
Gadolinium, Efficacy of Enbrel subcutaneously at Week 12, Efficacy of Enbrel subcutaneously at Week 24, Efficacy of Enbrel subcutaneously at Week 36, Efficacy of Enbrel subdermally at Week 12, Efficacy of Enbrel subdermally at Week 24, Efficacy of Enbrel subdermally at Week 36, PASI 75 n(%) subcutaneously at Week 12, PASI 75 n(%) subcutaneously at Week 24, PASI 75 n(%) subcutaneously at Week 36, PASI 75 n(%) subdermally at Week 12, PASI 75 n(%) subdermally at Week 24, PASI 75 n(%) subdermally at Week 36, Adverse Reactions of Enbrel subcutaneously, Adverse Reactions of Enbrel subdermally at Week 36
Drug
Lead sponsor
ASIS Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Westminster, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Sep 24, 2026, 5:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Functional Implications of TNF

NCT00729131
View directory record Official record
Conditions
Bronchitis
Interventions
Etanercept inhibition of ozone-induced airway hyper-responsiveness.
Drug
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2014 · Synced Sep 24, 2026, 5:16 PM EDT
Completed Phase 2 Interventional

Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes

NCT00434850
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogeneic Pancreatic Islet Cells, Deoxyspergualin, Antithymocyte globulin, Daclizumab or basiliximab, Sirolimus, Tacrolimus, Etanercept
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Sep 24, 2026, 5:16 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis

NCT02986139
View directory record Official record
Conditions
Arthritis, Rheumatoid; Arthritis, Psoriatic
Interventions
Commercial Formulation Etanercept, New Formulation Etanercept
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
29
States / cities
Birmingham, Alabama • El Cajon, California • Lomita, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Sep 24, 2026, 5:16 PM EDT
Not listed Phase 4 Interventional

Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis

NCT01793519
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, Infliximab, Adalimumab, Placebo
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 24, 2026, 5:16 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)

NCT01597245
View directory record Official record
Conditions
Psoriasis
Interventions
80 mg ixekizumab Dosing Regimen, 50 mg etanercept, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
41
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Sep 24, 2026, 5:16 PM EDT
Not listed Phase 4 Interventional

An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use

NCT01132235
View directory record Official record
Conditions
Psoriasis
Interventions
etanercept
Biological
Lead sponsor
Florida Academic Dermatology Centers
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2010 · Synced Sep 24, 2026, 5:16 PM EDT
Withdrawn Phase 4 Interventional

Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants

NCT01009879
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 24, 2026, 5:16 PM EDT
Completed Phase 1 Interventional

TNF-Alpha Inhibition for Treatment of Alzheimer's Disease

NCT00203320
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
etanercept given by perispinal administration
Drug
Lead sponsor
Tobinick, Edward Lewis, M.D.
Other
Eligibility
0 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2006 · Synced Sep 24, 2026, 5:16 PM EDT
Completed Phase 3 Interventional Results available

Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)

NCT02115750
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, CHS-0214
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
647 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
37
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Sep 24, 2026, 5:16 PM EDT
Completed Phase 4 Interventional Results available

Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)

NCT01313208
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
etanercept, Placebo, DMARD Therapy
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
38
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 24, 2026, 5:16 PM EDT
Not listed Phase 3 Interventional

The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis

NCT00012506
View directory record Official record
Conditions
Uveitis, Arthritis, Juvenile Rheumatoid
Interventions
TNFR:Fc
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 24, 2026, 5:16 PM EDT
Completed Phase 3 Interventional

Efficacy of Islet After Kidney Transplantation

NCT00468117
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet transplantation, Antithymocyte Globulin, Daclizumab or Basiliximab, Etanercept, Allogenic human purified pancreatic islets
Procedure · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 68 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
9
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Sep 24, 2026, 5:16 PM EDT
Completed Phase 2 Interventional Results available

Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT)

NCT00141739
View directory record Official record
Conditions
Graft-Versus-Host Disease
Interventions
Etanercept
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
1 Year to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
2
States / cities
Maywood, Illinois • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 24, 2026, 5:16 PM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease

NCT00841789
View directory record Official record
Conditions
Mucocutaneous Lymph Node Syndrome, Kawasaki Disease
Interventions
Etanercept, Placebo
Drug
Lead sponsor
Michael Portman
Other
Eligibility
2 Months to 20 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
7
States / cities
New Hyde Park, New York • New York, New York • The Bronx, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 24, 2026, 5:16 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

NCT00679042
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islets of Langerhans transplantation
Biological
Lead sponsor
CellTrans Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 24, 2026, 5:16 PM EDT
Terminated Phase 2Phase 3 Interventional

Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia

NCT00127387
View directory record Official record
Conditions
Lung Cancer, Prostate Cancer, Neoplasm Metastasis, Bone Cancer
Interventions
Enbrel
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Sep 24, 2026, 5:16 PM EDT